• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Trending
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Altimmune

weigh scale goliath outweigh balance bigger smaller even
Biotech

Altimmune touts 'best-in-class' lean mass data in weight loss

After a full data analysis, Altimmune is heralding ph. 2 pemvidutide data as “best-in-class” for spurring weight loss while preserving lean mass.
Annalee Armstrong Jun 23, 2024 1:45pm
stop shut down close end button

Altimmune bails on hepatitis B after phase 2 data disappoint

Mar 27, 2024 7:57am
rocket snail slow leapfrog beat fast win jump over

As Madrigal lands MASH nod, what's next for biotechs in pursuit?

Mar 15, 2024 10:55am
heart money

Altimmune puts heart health at center of phase 2 obesity data

Dec 1, 2023 8:18am
stock market down crash fail shares

Analyst sees path for Altimmune obesity drug despite stock drop

Mar 22, 2023 10:27am
target goal darts

Altimmune hits NASH target in phase 1 trial

Sep 14, 2022 11:45am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings